MiniMed Group Inc（MMED）股票分析MMEDMiniMed Group Inc

MiniMed Group, Inc. is an insulin delivery company advancing automated therapy for people with diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear. It operates in the Healthcare sector.

MiniMed Group, Inc. is not a good buy right now due to its current price of $17.49 being below the analyst price targets ranging from $22 to $29, indicating limited upside potential. Additionally, the RSI is at 33.407, suggesting the stock is oversold, but the negative sentiment from investors regarding Medtronic's abandonment of the brand poses a significant risk. The company also reported a net income loss of -119 million USD in Q3 2026, which raises concerns about its profitability and future growth prospects.